BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol. 2005;100:1311-1316. [PMID: 15929762 DOI: 10.1111/j.1572-0241.2005.41543.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ono A. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat. 2010;17:488-492. [PMID: 19840366 DOI: 10.1111/j.1365-2893.2009.01211.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
2 Aguilar C. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease. Blood Coagul Fibrinolysis. 2013;24:231-236. [PMID: 23518832 DOI: 10.1097/MBC.0b013e3283606a0b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Wang X, Jiang W, Li F, Hua F, Zhan Y, Li Y, Ji L, Zou S, Min Z, Song D, Cheng Y. Abnormal platelet kinetics are detected before the occurrence of thrombocytopaenia in HBV-related liver disease. Liver Int 2014;34:535-43. [DOI: 10.1111/liv.12309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G, De Gottardi A, Alberio L. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. Hepatology 2020;71:2135-48. [PMID: 32090357 DOI: 10.1002/hep.31201] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
5 Stasi R, Chia LW, Kalkur P, Lowe R, Shannon MS. Pathobiology and treatment of hepatitis virus-related thrombocytopenia. Mediterr J Hematol Infect Dis 2009;1:e2009023. [PMID: 21415958 DOI: 10.4084/MJHID.2009.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
6 Ikarashi Y, Kodama K, Taniai M, Hashimoto E, Tokushige K. The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus. Intern Med 2018;57:1065-70. [PMID: 29269684 DOI: 10.2169/internalmedicine.9853-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zhou L, Zhang LZ, Wang JY, Li YW, Hu HD, Peng XM, Zhao Y, Wang XM, Xie H, Liu CZ, Wang HM. Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia. Mol Clin Oncol 2017;7:435-42. [PMID: 28811901 DOI: 10.3892/mco.2017.1345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen YC, Ko PH, Lee CC, Tseng CW, Tseng KC. Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy. BMC Gastroenterol 2021;21:30. [PMID: 33478399 DOI: 10.1186/s12876-021-01606-x] [Reference Citation Analysis]
9 Helaly AZ, Al-Warraky MS, El-Azab GI, Kohla MA, Abdelaal EE. Portal and splanchnic hemodynamics after partial splenic embolization in cirrhotic patients with hypersplenism. APMIS 2015;123:1032-9. [PMID: 26547369 DOI: 10.1111/apm.12470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
10 González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, Santolaria-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 2016;22:4427-37. [PMID: 27182154 DOI: 10.3748/wjg.v22.i18.4427] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
11 Hu M, Wang Y, Liu Z, Yu Z, Guan K, Liu M, Wang M, Tan J, Huang L. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat Nanotechnol 2021;16:466-77. [PMID: 33495618 DOI: 10.1038/s41565-020-00836-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol 2020;54:503-11. [PMID: 32195771 DOI: 10.1097/MCG.0000000000001338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Okabayashi T, Hanazaki K. Overwhelming postsplenectomy infection syndrome in adults - a clinically preventable disease. World J Gastroenterol. 2008;14:176-179. [PMID: 18186551 DOI: 10.3748/wjg.14.176] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
14 Nwokediuko SC, Ibegbulam O. Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. Gastroenterology Res 2009;2:344-9. [PMID: 27990204 DOI: 10.4021/gr2009.12.1329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, Van Geet C, Cassiman D. Review article: Blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27:1017-1029. [PMID: 18331464 DOI: 10.1111/j.1365-2036.2008.03674.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 83] [Article Influence: 7.8] [Reference Citation Analysis]
16 Takahashi K. Platelet therapy: A novel strategy for liver regeneration, anti-fibrosis, and anti-apoptosis. WJSP 2013;3:29. [DOI: 10.5412/wjsp.v3.i3.29] [Reference Citation Analysis]
17 Zucker ML, Hagedorn CH, Murphy CA, Stanley S, Reid KJ, Skikne BS. Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction. Int J Lab Hematol 2012;34:525-32. [PMID: 22708981 DOI: 10.1111/j.1751-553X.2012.01429.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
18 Hayashi PH, Mehia C, Joachim Reimers H, Solomon HS, Bacon BR. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol. 2006;40:740-744. [PMID: 16940889 DOI: 10.1097/00004836-200609000-00015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
19 Jin W, Deng L, Zhang Q, Lin D, Zhu J, Chen Y, Chen B, Li J. A canine portal hypertension model induced by intra-portal administration of Sephadex microsphere. J Gastroenterol Hepatol. 2010;25:778-785. [PMID: 20492334 DOI: 10.1111/j.1440-1746.2009.06158.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
21 Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055-1065. [PMID: 16611265 DOI: 10.1111/j.1365-2036.2006.02889.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 8.3] [Reference Citation Analysis]
22 Zekry A, Freiman J. Eltrombopag: Is this "24 karat gold platelet" treatment for thrombocytopenia in cirrhosis associated with hepatitis C? Hepatology 2008;47:1418-21. [PMID: 18366111 DOI: 10.1002/hep.22300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Haegele S, Offensperger F, Pereyra D, Lahner E, Assinger A, Fleischmann E, Gruenberger B, Gruenberger T, Brostjan C, Starlinger P. Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction. PLoS One 2015;10:e0116985. [PMID: 25611592 DOI: 10.1371/journal.pone.0116985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
24 Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol 2012;47:1342-51. [PMID: 22674141 DOI: 10.1007/s00535-012-0600-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
25 Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol 2009;23:441-5. [PMID: 19543577 DOI: 10.1155/2009/591317] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
26 Trotter JF. Coagulation Abnormalities in Patients Who Have Liver Disease. Clinics in Liver Disease 2006;10:665-78. [DOI: 10.1016/j.cld.2006.08.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
27 Liu P, Hum J, Jou J, Scanlan RM, Shatzel J. Transfusion strategies in patients with cirrhosis. Eur J Haematol 2020;104:15-25. [PMID: 31661175 DOI: 10.1111/ejh.13342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Seth AK, Gunson BK, Mirza DF, Haydon G. Thrombocytosis in liver transplant recipients: Prevalence, natural history, and impact. Liver Transpl 2007;13:1598-602. [DOI: 10.1002/lt.21294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Anthony Lizarraga W, Dalia S, Reinert SE, Schiffman FJ. Venous thrombosis in patients with chronic liver disease. Blood Coagul Fibrinolysis. 2010;21:431-435. [PMID: 20595823 DOI: 10.1097/mbc.0b013e328337b3ba] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Wang P, Li Z, Ren S, Li J, Yang J, Kong G, Jiang A, Li Z. Spleen Regulates Hematopoietic Stem/Progenitor Cell Functions Through Regulation of EGF in Cirrhotic Hypersplenism. Dig Dis Sci 2018;63:1860-7. [DOI: 10.1007/s10620-018-5091-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Xianghong G, Guanping C, Fenghua Y, Jiayin W. Changes in platelet functional parameters and CD62 P expression in liver cirrhosis. Afr Health Sci 2013;13:1079-83. [PMID: 24940335 DOI: 10.4314/ahs.v13i4.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Joo EJ, Chang Y, Yeom JS, Lee YG, Ryu S. Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis. J Viral Hepat. 2017;24:253-258. [PMID: 27860000 DOI: 10.1111/jvh.12642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
33 Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48 Suppl 1:S68-S92. [PMID: 18304681 DOI: 10.1016/j.jhep.2008.01.021] [Cited by in Crossref: 190] [Cited by in F6Publishing: 145] [Article Influence: 14.6] [Reference Citation Analysis]
34 Sakamaki A, Watanabe T, Abe S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient. Clin J Gastroenterol 2017;10:261-4. [PMID: 28324272 DOI: 10.1007/s12328-017-0735-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
35 Benhammou JN, Aby ES, Shirvanian G, Manansala K, Hussain SK, Tong MJ. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. Sci Rep 2020;10:9902. [PMID: 32555268 DOI: 10.1038/s41598-020-66507-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Lau P, Ong V, Tan WT, Koh PL, Hartman M. Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding. Transfus Med Hemother 2012;39:139-50. [PMID: 22670132 DOI: 10.1159/000338034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
37 Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50. [PMID: 27186144 DOI: 10.2147/hmer.s74612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
38 Gunda DW, Godfrey KG, Kilonzo SB, Mpondo BC. Cytopenias among ART-naive patients with advanced HIV disease on enrolment to care and treatment services at a tertiary hospital in Tanzania: A cross-sectional study. Malawi Med J 2017;29:43-52. [PMID: 28567196 DOI: 10.4314/mmj.v29i1.9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
39 Afdhal N, Mchutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. Journal of Hepatology 2008;48:1000-7. [DOI: 10.1016/j.jhep.2008.03.009] [Cited by in Crossref: 328] [Cited by in F6Publishing: 254] [Article Influence: 25.2] [Reference Citation Analysis]
40 Sekiguchi T, Nagamine T, Takagi H, Mori M. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol 2006;12:1205-10. [PMID: 16534872 DOI: 10.3748/wjg.v12.i8.1205] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
41 Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778-93. [PMID: 27860293 DOI: 10.1111/liv.13317] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 13.2] [Reference Citation Analysis]
42 Yu C, Jiang Z, Hou A, Mu Y, Liu W, Tan S. Shen-Cao granules formulated based on traditional Chinese medicine alleviates bone marrow suppression caused by platinum-based anticancer reagents. Medicine (Baltimore) 2017;96:e6818. [PMID: 28489759 DOI: 10.1097/MD.0000000000006818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Mauss S, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Link R, Teuber G, Herrmann A, Spelter M. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18:e81-e90. [PMID: 20849436 DOI: 10.1111/j.1365-2893.2010.01372.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
44 Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun 2019;3:1423-34. [PMID: 31701067 DOI: 10.1002/hep4.1423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
45 Smith M, Ray CE. Splenic artery embolization as an adjunctive procedure for portal hypertension. Semin Intervent Radiol. 2012;29:135-139. [PMID: 23729984 DOI: 10.1055/s-0032-1312575] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
46 Dang SS, Wang WJ, Gao N, Wang SD, Li M, Liu LY, Sun MZ, Dong T. Apoptotic bone marrow CD34+ cells in cirrhotic patients. World J Gastroenterol. 2011;17:2044-2048. [PMID: 21528085 DOI: 10.3748/wjg.v17.i15.2044] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Franchini M, Montagnana M, Targher G, Zaffanello M, Lippi G. The use of recombinant factor VIIa in liver diseases. Blood Coagulation & Fibrinolysis 2008;19:341-8. [DOI: 10.1097/mbc.0b013e32830496a7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
48 Abdelmalek MF, Hellner LB, Zumberg M, Melgen VW, Lottenberg R. Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection. Dig Dis Sci 2007;52:914-9. [PMID: 17347887 DOI: 10.1007/s10620-006-9319-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Temel T, Cansu DU, Temel HE, Ozakyol AH. Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis. Hepat Mon 2014;14:e18556. [PMID: 24976834 DOI: 10.5812/hepatmon.18556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
50 Watanabe M, Murata S, Hashimoto I, Nakano Y, Ikeda O, Aoyagi Y, Matsuo R, Fukunaga K, Yasue H, Ohkohchi N. Platelets contribute to the reduction of liver fibrosis in mice. J Gastroenterol Hepatol. 2009;24:78-89. [PMID: 18624898 DOI: 10.1111/j.1440-1746.2008.05497.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
51 Zeng DW, Zhang JM, Liu YR, Dong J, Wu YL, Lin S, Jiang JJ, Zhu YY. A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity. Clin Res Hepatol Gastroenterol. 2014;38:727-734. [PMID: 25048838 DOI: 10.1016/j.clinre.2014.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
52 Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20:2595-2605. [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
53 Poordad FF, Sigal SH, Brown RS. Pathophysiologic basis for the medical management of portal hypertension. Expert Opin Pharmacother. 2009;10:453-467. [PMID: 19191681 DOI: 10.1517/14656560802707853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Northup P, Reutemann B. Management of Coagulation and Anticoagulation in Liver Transplantation Candidates. Liver Transpl 2018;24:1119-32. [DOI: 10.1002/lt.25198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
55 Hayashi H, Beppu T, Masuda T, Mizumoto T, Takahashi M, Ishiko T, Takamori H, Kanemitsu K, Hirota M, Baba H. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol. 2007;22:1638-1642. [PMID: 17683504 DOI: 10.1111/j.1440-1746.2007.05090.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
56 Nguyen KC, Zhang Y, Todd J, Kittle K, Patry D, Caldwell D, Lalande M, Smith S, Parks D, Navarro M, Massarsky A, Moon TW, Willmore WG, Tayabali AF. Biodistribution and Systemic Effects in Mice Following Intravenous Administration of Cadmium Telluride Quantum Dot Nanoparticles. Chem Res Toxicol 2019;32:1491-503. [DOI: 10.1021/acs.chemrestox.8b00397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
57 Lu S, Wang J, Liu S, Hung C, Chen C, Tung H, Chen T, Huang W, Lee C, Chen C, Changchien C. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006;107:2212-22. [DOI: 10.1002/cncr.22242] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
58 Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol 2011;55:1415-27. [PMID: 21718668 DOI: 10.1016/j.jhep.2011.06.008] [Cited by in Crossref: 107] [Cited by in F6Publishing: 84] [Article Influence: 10.7] [Reference Citation Analysis]
59 Bleibel W, Caldwell SH, Curry MP, Northup PG. Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. Transpl Int 2013;26:435-42. [DOI: 10.1111/tri.12064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
60 Rawi S, Wu GY. Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review. J Clin Transl Hepatol 2020;8:184-91. [PMID: 32832399 DOI: 10.14218/JCTH.2020.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
61 Flower O, Phillips LE, Cameron P, Gunn K, Dunkley S, Watts A, Rajbhandari D. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand. Blood Coagul Fibrinolysis 2010;21:207-15. [PMID: 20182351 DOI: 10.1097/MBC.0b013e3283333589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
62 Ikeda Y, Miyakawa Y. Development of thrombopoietin receptor agonists for clinical use. J Thromb Haemost 2009;7 Suppl 1:239-44. [PMID: 19630808 DOI: 10.1111/j.1538-7836.2009.03440.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
63 Luz JH, Luz PM, Marchiori E, Rodrigues LA, Gouveia HR, Martin HS, Faria IM, Souza RR, Gil RA, Palladino AM, Pimenta KB, de Souza HS. Partial splenic embolization to permit continuation of systemic chemotherapy. Cancer Med 2016;5:2715-20. [PMID: 27611010 DOI: 10.1002/cam4.856] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
64 Watanabe Y, Horiuchi A, Yoshida M, Yamamoto Y, Sugishita H, Kumagi T, Hiasa Y, Kawachi K. Significance of laparoscopic splenectomy in patients with hypersplenism. World J Surg. 2007;31:549-555. [PMID: 17308852 DOI: 10.1007/s00268-006-0504-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
65 Sheikh MY, Raoufi R, Atla PR, Riaz M, Oberer C, Moffett MJ. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. Saudi J Gastroenterol 2012;18:257-62. [PMID: 22824769 DOI: 10.4103/1319-3767.98431] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
66 Lv Y, Lau WY, Li Y, Deng J, Han X, Gong X, Liu N, Wu H. Hypersplenism: History and current status. Exp Ther Med 2016;12:2377-82. [PMID: 27703501 DOI: 10.3892/etm.2016.3683] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
67 Weksler BB. Review article: the pathophysiology of th-rombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:13-19. [PMID: 17958515 DOI: 10.1111/j.1365-2036.2007.03512.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
68 Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol. 2007;18:463-481. [PMID: 17446537 DOI: 10.1016/j.jvir.2006.12.734] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
69 Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2019;17:595-606. [PMID: 30273751 DOI: 10.1016/j.cgh.2018.09.043] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 14.7] [Reference Citation Analysis]
70 Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer. 2008;112:2283-2288. [PMID: 18344210 DOI: 10.1002/cncr.23432] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
71 Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol 2014;77:532-44. [PMID: 24117976 DOI: 10.1111/bcp.12244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]